Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Brief Summary: The purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back (relapsed) or did not respond to previous treatment (refractory).


Options:
A: Arm Label: Arm A: JCAR017 in combination with Durvalumab; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: Durvalumab | Arm Label: Arm B: JCAR017 in combination with CC-122; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: CC-122 | Arm Label: Arm C: JCAR017 in combination with CC-220; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: CC-220 | Arm Label: Arm D: JCAR017 in combination with Ibrutinib; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: Ibrutinib | Arm Label: Arm E: JCAR017 in combination with relatlimab and/or nivolumab; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: Relatlimab, Drug: Nivolumab | Arm Label: Arm F: JCAR017 in combination with CC-99282; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: CC-99282 | Intervention Type: BIOLOGICAL; Name: JCAR017; Assigned to Arm(s): Arm A: JCAR017 in combination with Durvalumab, Arm B: JCAR017 in combination with CC-122, Arm C: JCAR017 in combination with CC-220, Arm D: JCAR017 in combination with Ibrutinib, Arm E: JCAR017 in combination with relatlimab and/or nivolumab, Arm F: JCAR017 in combination with CC-99282 | Intervention Type: DRUG; Name: Durvalumab; Assigned to Arm(s): Arm A: JCAR017 in combination with Durvalumab | Intervention Type: DRUG; Name: CC-122; Assigned to Arm(s): Arm B: JCAR017 in combination with CC-122 | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Arm D: JCAR017 in combination with Ibrutinib | Intervention Type: DRUG; Name: CC-220; Assigned to Arm(s): Arm C: JCAR017 in combination with CC-220 | Intervention Type: DRUG; Name: Relatlimab; Assigned to Arm(s): Arm E: JCAR017 in combination with relatlimab and/or nivolumab | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Arm E: JCAR017 in combination with relatlimab and/or nivolumab | Intervention Type: DRUG; Name: CC-99282; Assigned to Arm(s): Arm F: JCAR017 in combination with CC-99282
B: Arm Label: Treatment (CD20-specific CAR T cell, chemotherapy); Type: EXPERIMENTAL; Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy, Drug: Cyclophosphamide, Other: Laboratory Biomarker Analysis, Procedure: Leukapheresis, Drug: Fludarabine Phosphate | Intervention Type: BIOLOGICAL; Name: Chimeric Antigen Receptor T-Cell Therapy; Assigned to Arm(s): Treatment (CD20-specific CAR T cell, chemotherapy) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Treatment (CD20-specific CAR T cell, chemotherapy) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Treatment (CD20-specific CAR T cell, chemotherapy) | Intervention Type: PROCEDURE; Name: Leukapheresis; Assigned to Arm(s): Treatment (CD20-specific CAR T cell, chemotherapy) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Treatment (CD20-specific CAR T cell, chemotherapy)
C: Arm Label: Mixed CD19/CD20 CAR-T Transfer; Type: EXPERIMENTAL; Interventions: Biological: Mixed CD19/CD20 CAR-T Transfer | Intervention Type: BIOLOGICAL; Name: Mixed CD19/CD20 CAR-T Transfer; Assigned to Arm(s): Mixed CD19/CD20 CAR-T Transfer
D: Arm Label: Tisagenlecleucel+Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: Tisagenlecleucel, Drug: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Tisagenlecleucel; Assigned to Arm(s): Tisagenlecleucel+Pembrolizumab | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Tisagenlecleucel+Pembrolizumab

Answer: B